Lancet Global Health: Improving Ebola virus disease outbreak control through targeted post-exposure prophylaxis
In this Viewpoint article in The Lancet Global Health, MSF’s Elin Hoffmann Dahl and co-authors discuss the benefits and limitations of different candidates for post-exposure prophylaxis (PEP), namely monoclonal antibodies, vaccines, and antiviral medicines, for both immediate and long-term protection against Ebola virus disease.
